Top-Rated StocksTop-RatedNASDAQ:CBAY CymaBay Therapeutics (CBAY) Stock Forecast, Price & News $14.83 +0.51 (+3.56%) (As of 09/26/2023 ET) Add Compare Share Share Today's Range$14.76▼$15.7050-Day Range$11.27▼$17.6252-Week Range$3.15▼$18.20Volume3.37 million shsAverage Volume1.91 million shsMarket Capitalization$1.64 billionP/E RatioN/ADividend YieldN/APrice Target$19.18 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability CymaBay Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.08 Rating ScoreUpside/Downside33.6% Upside$19.82 Price TargetShort InterestHealthy8.12% of Shares Sold ShortDividend StrengthN/ASustainability-0.88Upright™ Environmental ScoreNews Sentiment0.53Based on 14 Articles This WeekInsider TradingSelling Shares$2.17 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($0.93) to ($1.30) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.79 out of 5 starsMedical Sector73rd out of 964 stocksPharmaceutical Preparations Industry17th out of 442 stocks 4.5 Analyst's Opinion Consensus RatingCymaBay Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.08, and is based on 11 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $19.82, CymaBay Therapeutics has a forecasted upside of 33.6% from its current price of $14.83.Amount of Analyst CoverageCymaBay Therapeutics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 4.0 Short Interest Percentage of Shares Shorted8.12% of the outstanding shares of CymaBay Therapeutics have been sold short.Short Interest Ratio / Days to CoverCymaBay Therapeutics has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in CymaBay Therapeutics has recently decreased by 21.06%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldCymaBay Therapeutics does not currently pay a dividend.Dividend GrowthCymaBay Therapeutics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCymaBay Therapeutics has received a 74.24% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for CymaBay Therapeutics is -0.88. Previous Next 3.1 News and Social Media Coverage News SentimentCymaBay Therapeutics has a news sentiment score of 0.53. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.64 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 14 news articles for CymaBay Therapeutics this week, compared to 3 articles on an average week.Search Interest22 people have searched for CBAY on MarketBeat in the last 30 days. This is an increase of 47% compared to the previous 30 days.MarketBeat Follows19 people have added CymaBay Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 111% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, CymaBay Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,172,369.00 in company stock.Percentage Held by InsidersOnly 7.00% of the stock of CymaBay Therapeutics is held by insiders.Percentage Held by Institutions95.03% of the stock of CymaBay Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for CymaBay Therapeutics are expected to decrease in the coming year, from ($0.93) to ($1.30) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CymaBay Therapeutics is -16.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CymaBay Therapeutics is -16.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCymaBay Therapeutics has a P/B Ratio of 34.49. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About CymaBay Therapeutics (NASDAQ:CBAY) StockCymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of autoimmune liver disease, primary biliary cholangitis (PBC). The company also develops MBX-2982 for the disease/condition of hypoglycemia in type 1 diabetics. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC; and holds a worldwide license from Janssen Pharmaceuticals, Inc. to research, develop, and commercialize compounds with activity against an undisclosed metabolic disease target. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.Read More CBAY Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CBAY Stock News HeadlinesSeptember 26, 2023 | markets.businessinsider.comUBS Maintains Buy Rating for CymaBay Therapeutics: Here's What You Need To KnowSeptember 24, 2023 | americanbankingnews.comCymaBay Therapeutics, Inc. (NASDAQ:CBAY) Given Consensus Rating of "Buy" by AnalystsSeptember 26, 2023 | Chaikin Analytics (Ad)Buy This Stock for AI Tidal Wave (not NVDA)The internet boom made more millionaires than any tech - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.September 22, 2023 | markets.businessinsider.comB.Riley Financial Sticks to Its Buy Rating for CymaBay Therapeutics (CBAY)September 22, 2023 | americanbankingnews.comResearch Analysts Issue Forecasts for CymaBay Therapeutics, Inc.'s FY2023 Earnings (NASDAQ:CBAY)September 21, 2023 | finance.yahoo.comCymaBay Initiates AFFIRM, a Phase 3b/4 Study Evaluating the Effect of Seladelpar on Clinical Outcomes in Patients with Cirrhosis due to Primary Biliary CholangitisSeptember 21, 2023 | americanbankingnews.comCymaBay Therapeutics (NASDAQ:CBAY) Trading Down 3.5% Following Insider SellingSeptember 20, 2023 | finance.yahoo.comInsider Sell: Charles Mcwherter Sells 21,746 Shares of CymaBay Therapeutics Inc (CBAY)September 26, 2023 | Chaikin Analytics (Ad)Buy This Stock for AI Tidal Wave (not NVDA)The internet boom made more millionaires than any tech - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.September 15, 2023 | finance.yahoo.comCymaBay Therapeutics to Present at the Cantor Global Healthcare ConferenceSeptember 14, 2023 | finance.yahoo.comCymaBay Announces Closing of Upsized $258.7 Million Public Offering of Common Stock and Pre-Funded Warrants, Including Full Exercise of Underwriters’ Option to Purchase Additional SharesSeptember 12, 2023 | finance.yahoo.comWhy CymaBay Therapeutics Stock Triumphed Again on TuesdaySeptember 12, 2023 | finance.yahoo.comCymaBay Announces Pricing of Upsized $225 Million Public Offering of Common Stock and Pre-Funded WarrantsSeptember 11, 2023 | markets.businessinsider.comJonesTrading Remains a Buy on CymaBay Therapeutics (CBAY)September 11, 2023 | markets.businessinsider.comCymaBay Launches Public Offering Of $150 Mln Of Shares, WarrantsSeptember 8, 2023 | finance.yahoo.comCymaBay (CBAY) Stock Up on Positive Results From PBC StudySeptember 8, 2023 | finance.yahoo.comWhy CymaBay, With 159% Growth This Year, Just Surged For A Second Day RunningSeptember 8, 2023 | seekingalpha.comCymaBay Therapeutics: Shares Jump On Confirmatory Seladelpar Data - As Good As It Gets?September 7, 2023 | msn.comRaymond James Maintains Cymabay Therapeutics (CBAY) Strong Buy RecommendationSeptember 7, 2023 | markets.businessinsider.comB.Riley Financial Sticks to Their Buy Rating for CymaBay Therapeutics (CBAY)September 7, 2023 | marketwatch.comCymaBay Shares Leap Premarket on Phase 3 Seladelpar Study Success >CBAYSeptember 7, 2023 | msn.comCymaBay says liver disease candidate outperformed in Phase 3 trialSeptember 7, 2023 | markets.businessinsider.comCymaBay Therapeutics' Lead Drug Candidate Hits Main Goal In Pivotal Study For Liver DamageSeptember 7, 2023 | finance.yahoo.comCymaBay's Seladelpar Achieves High Statistical Significance for the Primary and Key Secondary Endpoints in the Phase 3 RESPONSE Trial in Primary Biliary CholangitisSeptember 6, 2023 | finance.yahoo.comCymaBay to Host Investor Call to Share Topline Results from the Phase 3 RESPONSE Trial of Seladelpar in Primary Biliary Cholangitis on September 7, 2023September 6, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: CymaBay Therapeutics (CBAY) and VistaGen Therapeutics (VTGN)August 29, 2023 | finanznachrichten.deCymaBay Therapeutics, Inc.: CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)See More Headlines Receive CBAY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CymaBay Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CBAY Company Calendar Last Earnings8/10/2023Today9/26/2023Next Earnings (Estimated)11/13/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CBAY CUSIPN/A CIK1042074 Webwww.cymabay.com Phone(510) 293-8800Fax510-293-9090Employees60Year FoundedN/APrice Target and Rating Average Stock Price Forecast$19.82 High Stock Price Forecast$33.00 Low Stock Price Forecast$12.00 Forecasted Upside/Downside+24.4%Consensus RatingBuy Rating Score (0-4)3.08 Research Coverage12 Analysts Profitability EPS (Most Recent Fiscal Year)($0.88) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-106,000,000.00 Net MarginsN/A Pretax Margin-260.27% Return on Equity-104.52% Return on Assets-41.77% Debt Debt-to-Equity Ratio0.92 Current Ratio12.52 Quick Ratio12.52 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.43 per share Price / Book35.86Miscellaneous Outstanding Shares110,360,000Free Float102,631,000Market Cap$1.70 billion OptionableOptionable Beta0.35 The Best High-Yield Dividend Stocks for 2023Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. Sujal A. Shah (Age 50)Pres, CEO & Director Comp: $1.04MDr. Charles A. McWherter Ph.D. (Age 68)Pres of R&D and Chief Scientific Officer Comp: $700.65kMr. Paul T. Quinlan (Age 60)Gen. Counsel, Chief Compliance Officer & Corp. Sec. Comp: $629.72kMr. Harish Shantharam C.F.A.Chief Financial OfficerMr. Ken BoehmSr. VP of HRMr. Patrick J. O'Mara (Age 62)Sr. VP of Bus. Devel. Dr. Robert L. Martin (Age 61)Sr. VP of Manufacturing & Nonclinical Devel. Ms. Klara A. Dickinson-Eason (Age 55)Chief Regulatory & Quality Assurance Officer Ms. Becki Filice (Age 62)Sr. VP of Portfolio & Product Leadership Mr. Lewis J. Stuart B.A. (Age 64)BA, M.B.A., MBA, Chief Commercial Officer More ExecutivesKey CompetitorsArcus BiosciencesNYSE:RCUSPacira BioSciencesNASDAQ:PCRXSupernus PharmaceuticalsNASDAQ:SUPNAbCellera BiologicsNASDAQ:ABCLZentalis PharmaceuticalsNASDAQ:ZNTLView All CompetitorsInsiders & InstitutionsCharles McwherterSold 21,746 sharesTotal: $352,720.12 ($16.22/share)Paul T. QuinlanSold 53,000 sharesTotal: $894,110.00 ($16.87/share)Perceptive Advisors LLCSold 170,000 shares on 8/24/2023Ownership: 3.804%Affinity Asset Advisors LLCSold 33,000 shares on 8/21/2023Ownership: 1.070%California State Teachers Retirement SystemBought 22,434 shares on 8/21/2023Ownership: 0.099%View All Insider TransactionsView All Institutional Transactions CBAY Stock - Frequently Asked Questions Should I buy or sell CymaBay Therapeutics stock right now? 12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for CymaBay Therapeutics in the last twelve months. There are currently 11 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CBAY shares. View CBAY analyst ratings or view top-rated stocks. What is CymaBay Therapeutics' stock price forecast for 2023? 12 analysts have issued 12-month price targets for CymaBay Therapeutics' shares. Their CBAY share price forecasts range from $12.00 to $33.00. On average, they anticipate the company's share price to reach $19.82 in the next twelve months. This suggests a possible upside of 28.5% from the stock's current price. View analysts price targets for CBAY or view top-rated stocks among Wall Street analysts. How have CBAY shares performed in 2023? CymaBay Therapeutics' stock was trading at $6.27 at the beginning of the year. Since then, CBAY shares have increased by 145.9% and is now trading at $15.42. View the best growth stocks for 2023 here. Are investors shorting CymaBay Therapeutics? CymaBay Therapeutics saw a decrease in short interest in August. As of August 31st, there was short interest totaling 8,960,000 shares, a decrease of 21.1% from the August 15th total of 11,350,000 shares. Based on an average daily volume of 2,410,000 shares, the short-interest ratio is currently 3.7 days. View CymaBay Therapeutics' Short Interest. When is CymaBay Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023. View our CBAY earnings forecast. How were CymaBay Therapeutics' earnings last quarter? CymaBay Therapeutics, Inc. (NASDAQ:CBAY) posted its quarterly earnings data on Thursday, August, 10th. The biopharmaceutical company reported ($0.01) earnings per share for the quarter, beating analysts' consensus estimates of ($0.21) by $0.20. The biopharmaceutical company had revenue of $31.02 million for the quarter, compared to analysts' expectations of $30.78 million. What ETFs hold CymaBay Therapeutics' stock? ETFs with the largest weight of CymaBay Therapeutics (NASDAQ:CBAY) stock in their portfolio include Invesco Biotechnology & Genome ETF (PBE), SPDR S&P Pharmaceuticals ETF (XPH), AdvisorShares Dorsey Wright Micro-Cap ETF (DWMC), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL) and ALPS Medical Breakthroughs ETF (SBIO).iShares Micro-Cap ETF (IWC). What other stocks do shareholders of CymaBay Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other CymaBay Therapeutics investors own include Sorrento Therapeutics (SRNE), NVIDIA (NVDA), Advanced Micro Devices (AMD), OPKO Health (OPK), Pfizer (PFE), Alibaba Group (BABA), Novavax (NVAX), Corbus Pharmaceuticals (CRBP), Energy Transfer (ET) and Viking Therapeutics (VKTX). What is CymaBay Therapeutics' stock symbol? CymaBay Therapeutics trades on the NASDAQ under the ticker symbol "CBAY." Who are CymaBay Therapeutics' major shareholders? CymaBay Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (7.70%), Cormorant Asset Management LP (3.87%), Perceptive Advisors LLC (3.80%), Franklin Resources Inc. (3.36%), State Street Corp (2.35%) and Geode Capital Management LLC (1.90%). Insiders that own company stock include Charles Mcwherter, Daniel Menold, Dennis D Kim, Paul T Quinlan and Sujal Shah. View institutional ownership trends. How do I buy shares of CymaBay Therapeutics? Shares of CBAY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is CymaBay Therapeutics' stock price today? One share of CBAY stock can currently be purchased for approximately $15.42. How much money does CymaBay Therapeutics make? CymaBay Therapeutics (NASDAQ:CBAY) has a market capitalization of $1.70 billion. The biopharmaceutical company earns $-106,000,000.00 in net income (profit) each year or ($0.88) on an earnings per share basis. How can I contact CymaBay Therapeutics? CymaBay Therapeutics' mailing address is 7575 GATEWAY BOULEVARD SUITE 110, NEWARK CA, 94560. The official website for the company is www.cymabay.com. The biopharmaceutical company can be reached via phone at (510) 293-8800, via email at investors@cymabay.com, or via fax at 510-293-9090. This page (NASDAQ:CBAY) was last updated on 9/26/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CymaBay Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.